A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS).
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs ABT 288 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 11 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.